F-1/A: NuCana PLC Announces Offering of ADSs and Warrants to Bolster Cancer Treatment Programs

NuCana PLC plans to raise capital through a public offering of American Depositary Shares (ADSs) and warrants to advance its ProTide technology-based cancer treatment pipeline.

Summary

• NuCana PLC is undertaking a public offering involving ADSs, Series A warrants, Series B warrants, and pre-funded warrants.
• The offering aims to raise funds for drug discovery and development programs, working capital, and potential acquisitions.
• Each ADS or pre-funded warrant is offered with a Series A warrant and a Series B warrant.
• The assumed combined public offering price is $0.5601 per ADS and accompanying warrants.
• Series A warrants have an exercise price of 125% of the combined public offering price and expire five years from the issuance date.
• Series B warrants have an exercise price of 250% of the combined public offering price and expire two and a half years from the issuance date.
• The Series B warrants include a zero exercise price option under certain conditions, potentially increasing the number of ADSs issued upon exercise.
• Pre-funded warrants are offered in lieu of ADSs to investors who would exceed beneficial ownership limitations, with a nominal exercise price.
• The offering is conducted on a reasonable best efforts basis with Laidlaw & Company (UK) Ltd. acting as the placement agent.
• The company estimates net proceeds of approximately $5.5 million from the offering, after deducting placement agent fees and estimated offering expenses.

Sentiment

Score: 4

Explanation: The document is largely factual, but the terms of the offering (particularly the potential for dilution and the zero exercise price option) suggest some financial challenges for the company. The sentiment is therefore slightly negative.

Positives

• The offering will provide additional capital to advance NuCana's drug discovery and development programs.
• The funds can also be used for working capital, capital expenditures, and potential strategic investments.
• The company has a system of internal accounting controls sufficient to provide reasonable assurance that transactions are executed in accordance with management's general or specific authorizations.
• The company is in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours.

Negatives

• The offering may cause dilution to existing shareholders.
• The company does not expect to receive any cash proceeds from the exercise of the Series B Warrants because it is highly unlikely that a Series B Warrant holder will elect to pay an exercise price in cash to receive one ADS when they could elect the zero exercise price option in these circumstances to receive more ADSs than they would receive if they did pay an exercise price.
• The company may not be able to raise the amount of capital it believes is required for its operations in the short-term and may need to raise additional funds, which may not be available or available on terms acceptable to us.

Risks

• The company may not effectively use the net proceeds from the offering.
• The company may experience future dilution as a result of future equity offerings.
• Sales of a substantial number of our ADSs in the public markets, or the perception that such sales could occur, could cause our ADS price to fall.
• The exercise of our outstanding options will dilute shareholders and ADS holders and could decrease our ADS price.
• There is no public market for the Pre-Funded Warrants, Series A Warrants or Series B Warrants being offered in this offering.
• The Series A Warrants and Series B Warrants may not have value.
• This is a best efforts offering, no minimum amount of securities is required to be sold, and we may not raise the amount of capital we believe is required for our business plans, including our near-term business plans.
• This offering may result in an immediate trading halt or delisting of our ADSs from The Nasdaq Capital Market due to public interest concerns.
• This offering may cause the price of our ADSs to decline and fall below the minimum bid price requirement required by the Nasdaq Listing Rules, which could result in our ADSs being delisted from The Nasdaq Capital Market.

Future Outlook

The company estimates that the net proceeds of this offering and current cash will be sufficient to fund operating expenses and capital expenditure requirements at least through 2026.

Industry Context

This announcement reflects a common strategy in the biopharmaceutical industry where companies raise capital to fund ongoing research and development activities, particularly for clinical-stage programs.

Comparison to Industry Standards

• The structure of this offering, including ADSs, warrants, and pre-funded warrants, is a relatively common approach used by small to mid-cap biopharmaceutical companies to raise capital.
• Comparable companies that have used similar structures include [Comparable Company 1] and [Comparable Company 2], although the specific terms (exercise prices, warrant durations, etc.) vary based on company-specific factors and market conditions.
• The use of a 'best efforts' placement agent is also standard for companies of NuCana's size, as it allows for flexibility in the amount of capital raised.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares and warrants.
• The company's ability to fund its drug development programs could be enhanced, potentially benefiting patients.
• Employees may benefit from the company's increased financial stability and growth prospects.

Next Steps

• The company will proceed with the offering, seeking to secure the targeted funding.
• The company will file the Prospectus with the Commission pursuant to Rule 424(b).
• The company will apply to list or quote all of the Shares and Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and Warrant Shares on such Trading Market.

Key Dates

Keywords

ADSs, warrants, NuCana, offering, Series A, Series B, pre-funded, exercise price, dilution, capital, NCNA, Laidlaw, ProTide, cancer